{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:41:56Z","timestamp":1790383316289,"version":"4.1.0"},"reference-count":52,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Urinary tract infections (UTIs) are very frequent in women and can be caused by a range of pathogens. High recurrence rates and increasing antibiotic resistance of uropathogens make UTIs a severe public health problem. d-mannose is a monosaccharide that can inhibit bacterial adhesion to the urothelium after oral intake. Several clinical studies have shown the efficacy of d-mannose in the prevention of recurrent UTIs; these also provided limited evidence for the efficacy of d-mannose in acute therapy. A recent prospective, non-interventional study in female patients with acute cystitis reported good success rates for treatment with d-mannose. Here, we present data from a post hoc analysis of this study to compare the cure rate of d-mannose monotherapy with that of antibiotics. The results show that d-mannose is a promising alternative to antibiotics in the treatment of acute uncomplicated UTIs in women.<\/jats:p>","DOI":"10.3390\/antibiotics11030314","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T20:46:17Z","timestamp":1645994777000},"page":"314","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Why d-Mannose May Be as Efficient as Antibiotics in the Treatment of Acute Uncomplicated Lower Urinary Tract Infections\u2014Preliminary Considerations and Conclusions from a Non-Interventional Study"],"prefix":"10.3390","volume":"11","author":[{"given":"Florian","family":"Wagenlehner","sequence":"first","affiliation":[{"name":"Clinic and Polyclinic for Urology, Pediatric Urology and Andrology, Justus-Liebig-University Giessen, 35392 Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Lorenz","sequence":"additional","affiliation":[{"name":"BBS-B\u00fcro f\u00fcr Biometrie und Statistik, Im Unterfeld 17, 63543 Neuberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oda","family":"Ewald","sequence":"additional","affiliation":[{"name":"MCM Klosterfrau Vertriebsgesellschaft mbH, Gereonsmuehlengasse 1-11, 50670 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gerke","sequence":"additional","affiliation":[{"name":"MCM Klosterfrau Vertriebsgesellschaft mbH, Gereonsmuehlengasse 1-11, 50670 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1007\/s00345-019-03071-4","article-title":"Epidemiology of urological infections: A global burden","volume":"38","author":"Murt","year":"2020","journal-title":"World J. Urol."},{"key":"ref_2","unstructured":"Leitlinienprogramm DGU: Interdisziplin\u00e4re S3 Leitlinie: Epidemiologie, Diagnostik, Therapie, Pr\u00e4vention und Management Unkomplizierter, Bakterieller, Ambulant Erworbener Harnwegsinfektionen Bei Erwachsenen Patienten (2021, October 29). Langversion 1.1-2, 2017 AWMF Registernummer: 043\/044. Available online: https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/043-044l_S3_Harnwegsinfektionen_2017-05.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Sarshar, M., Behzadi, P., Ambrosi, C., Zagaglia, C., Palamara, A.T., and Scribano, D. (2020). FimH and Anti-Adhesive Therapeutics: A Disarming Strategy Against Uropathogens. Antibiotics, 9.","DOI":"10.3390\/antibiotics9070397"},{"key":"ref_4","unstructured":"Bonkat, G., Bartoletti, R., Bruy\u00e8re, F., Cai, T., Geerlings, S.E., K\u00f6ves, B., Schubert, S., and Wagenlehner, F.M. (2021). EAU Guidelines on Urological Infections, EAU Guidelines Office."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","article-title":"Urinary tract infection syndromes: Occurrence, recurrence, bacteriology, risk factors, and disease burden","volume":"28","author":"Foxman","year":"2014","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1756287218814382","DOI":"10.1177\/1756287218814382","article-title":"Risk factors and predisposing conditions for urinary tract infection","volume":"11","author":"Storme","year":"2019","journal-title":"Ther. Adv. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: Epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Walker","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.eururo.2020.06.032","article-title":"The EAU and AUA\/CUA\/SUFU Guidelines on Recurrent Urinary Tract Infections: What is the Difference?","volume":"78","author":"Naber","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bischoff, S., Walter, T., Gerigk, M., Ebert, M., and Vogelmann, R. (2018). Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-2960-9"},{"key":"ref_10","unstructured":"World Health Organization (2014). Antimicrobial Resistance: Global Report on Surveillance, World Health Organization."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/tog.12644","article-title":"Recurrent urinary tract infections: A critical review of the currently available treatment options","volume":"22","author":"Negus","year":"2020","journal-title":"Obstet. Gynaecol."},{"key":"ref_12","unstructured":"European Centre for Disease Prevention and Control (2021, November 16). Antimicrobial Resistance. Available online: https:\/\/www.ecdc.europa.eu\/en\/antimicrobial-resistance."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/oxfordjournals.aje.a010170","article-title":"Risk factors for second urinary tract infection among college women","volume":"151","author":"Foxman","year":"2000","journal-title":"Am. J. Epidemiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3390\/antibiotics3030341","article-title":"Uncomplicated Urinary Tract Infections and Antibiotic Resistance-Epidemiological and Mechanistic Aspects","volume":"3","author":"Wiedemann","year":"2014","journal-title":"Antibiotics"},{"key":"ref_15","unstructured":"European Centre for Disease Prevention and Control (2021, November 16). ECDC\/EMEA Joint Technical Report. The Bacterial Challenge: Time to React., Available online: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/media\/en\/publications\/Publications\/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf."},{"key":"ref_16","first-page":"107","article-title":"Social and economic burden of recurrent urinary tract infections and quality of life: A patient web-based study (GESPRIT)","volume":"18","author":"Wagenlehner","year":"2018","journal-title":"Expert Rev. Pharm. Outcomes Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3389\/fmicb.2017.01566","article-title":"UroPathogenic Escherichia coli (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-antibiotic Antimicrobial Strategies","volume":"8","author":"Terlizzi","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_18","first-page":"2920","article-title":"D-mannose: A promising support for acute urinary tract infections in women. A pilot study","volume":"20","author":"Domenici","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/emboj.2008.155","article-title":"Architectures and biogenesis of non-flagellar protein appendages in Gram-negative bacteria","volume":"27","author":"Fronzes","year":"2008","journal-title":"EMBO J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1242\/jcs.114.22.4095","article-title":"Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: Evidence from in vitro FimH binding","volume":"114","author":"Zhou","year":"2001","journal-title":"J. Cell Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10738","DOI":"10.1038\/ncomms10738","article-title":"Catch-bond mechanism of the bacterial adhesin FimH","volume":"7","author":"Sauer","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/336682a0","article-title":"Conservation of the D-mannose-adhesion protein among type 1 fimbriated members of the family Enterobacteriaceae","volume":"336","author":"Abraham","year":"1988","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wellens, A., Garofalo, C., Nguyen, H., Van Gerven, N., Sl\u00e4tteg\u00e5rd, R., Hernalsteens, J.P., Wyns, L., Oscarson, S., De Greve, H., and Hultgren, S. (2008). Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex. PLoS ONE, 3.","DOI":"10.1371\/annotation\/ea59d179-0a71-4836-86f0-8d375f5df089"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/2051415813518332","article-title":"Oral D-mannose in recurrent urinary tract infections in women: A pilot study","volume":"7","author":"Porru","year":"2014","journal-title":"J. Clin. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00345-013-1091-6","article-title":"D-mannose powder for prophylaxis of recurrent urinary tract infections in women: A randomized clinical trial","volume":"32","author":"Altarac","year":"2014","journal-title":"World J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/nau.23173","article-title":"Open label feasibility study evaluating D-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis","volume":"36","author":"Pakzad","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"265.e1","DOI":"10.1016\/j.ajog.2020.05.048","article-title":"D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: A systematic review and meta-analysis","volume":"223","author":"Lenger","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1001\/jama.287.20.2701","article-title":"Does this woman have an acute uncomplicated urinary tract infection?","volume":"287","author":"Bent","year":"2002","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00120-015-3873-5","article-title":"German validation of the Acute Cystitis Symptom Score","volume":"54","author":"Alidjanov","year":"2015","journal-title":"Urologe A"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000356177","article-title":"New self-reporting questionnaire to assess urinary tract infections and differential diagnosis: Acute cystitis symptom score","volume":"92","author":"Alidjanov","year":"2014","journal-title":"Urol. Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000448591","article-title":"The Acute Cystitis Symptom Score for Patient-Reported Outcome Assessment","volume":"97","author":"Alidjanov","year":"2016","journal-title":"Urol. Int."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Alidjanov, J.F., Naber, K.G., Abdufattaev, U.A., Pilatz, A., and Wagenlehner, F.M. (2018). Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part II. Patient-Reported Outcome Assessment. Antibiotics, 7.","DOI":"10.3390\/antibiotics7020043"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000493509","article-title":"Reliability of Symptom-Based Diagnosis of Uncomplicated Cystitis","volume":"102","author":"Alidjanov","year":"2019","journal-title":"Urol. Int."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Alidjanov, J.F., Naber, K.G., Abdufattaev, U.A., Pilatz, A., and Wagenlehner, F.M. (2018). Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part I. Development, Diagnosis and Differential Diagnosis. Antibiotics, 7.","DOI":"10.3390\/antibiotics7010006"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00345-019-02761-3","article-title":"Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women","volume":"38","author":"Alidjanov","year":"2020","journal-title":"World J. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00345-019-02948-8","article-title":"Additional assessment of Acute Cystitis Symptom Score questionnaire for patient-reported outcome measure in female patients with acute uncomplicated cystitis: Part II","volume":"38","author":"Alidjanov","year":"2020","journal-title":"World J. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4111\/icu.20200060","article-title":"Acute Cystitis Symptom Score questionnaire for measuring patient-reported outcomes in women with acute uncomplicated cystitis: Clinical validation as part of a phase III trial comparing antibiotic and nonantibiotic therapy","volume":"61","author":"Alidjanov","year":"2020","journal-title":"Investig. Clin. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000493368","article-title":"Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial","volume":"101","author":"Wagenlehner","year":"2018","journal-title":"Urol. Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00120-017-0327-2","article-title":"New questionnaire for the German validation of the Acute Cystitis Symptom Score","volume":"56","author":"Alidjanov","year":"2017","journal-title":"Urol. A"},{"key":"ref_40","unstructured":"Food and Drug Administration (FDA) (2021, November 16). Uncomplicated Urinary Tract Infections: Developing Drugs for Treatment, Guidance for Industry., Available online: https:\/\/www.fda.gov\/media\/129531\/download."},{"key":"ref_41","unstructured":"European Medicines Agency (EMA) (2021, November 16). Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections. Rev 3., Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf."},{"key":"ref_42","first-page":"4","article-title":"Nicht interventionelle Studie mit Femannose\u00ae N zur Untersuchung von Vertr\u00e4glichkeit, Lebensqualit\u00e4t und Symptomverlauf bei akuter unkomplizierter Harnweginfektion [Non-interventional study with Femannose\u00ae N to investigate tolerance, quality of life and course of symptoms in acute uncomplicated urinary tract infection]","volume":"29","author":"Wagenlehner","year":"2020","journal-title":"J. Pharmakol Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/00031305.2000.10474560","article-title":"Simple and Effective Confidence Intervals for Proportions and Differences of Proportions Result from Adding Two Successes and Two Failures","volume":"54","author":"Agresti","year":"2000","journal-title":"Am. Stat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/jac\/dkq237","article-title":"Fosfomycin versus other antibiotics for the treatment of cystitis: A meta-analysis of randomized controlled trials","volume":"65","author":"Falagas","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jgar.2020.01.027","article-title":"Systematic review and meta-analysis to estimate the antibacterial treatment effect of nitrofurantoin for a non-inferiority trial in uncomplicated urinary tract infection","volume":"22","author":"Raychaudhuri","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/1874285801913010193","article-title":"Single-Dose Fosfomycin Trometamol Versus Other Antimicrobial Regimens For Treatment of Uncomplicated Lower Urinary Tract Infection: A Systematic Review And Meta-Analysis","volume":"13","author":"Alfaresi","year":"2019","journal-title":"Open Microbiol. J."},{"key":"ref_47","first-page":"h6544","article-title":"Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: Randomised controlled trial","volume":"351","author":"Bleidorn","year":"2015","journal-title":"BMJ"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"j4784","DOI":"10.1136\/bmj.j4784","article-title":"Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: Randomised, double blind trial","volume":"359","author":"Kronenberg","year":"2017","journal-title":"BMJ"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Vik, I., Bollestad, M., Grude, N., B\u00e6rheim, A., Damsgaard, E., Neumark, T., Bjerrum, L., Cordoba, G., Olsen, I.C., and Lindb\u00e6k, M. (2018). Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial. PLoS Med., 15.","DOI":"10.1371\/journal.pmed.1002569"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Bleidorn, J., G\u00e1gyor, I., Kochen, M.M., Wegscheider, K., and Hummers-Pradier, E. (2010). Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection?--results of a randomized controlled pilot trial. BMC Med., 8.","DOI":"10.1186\/1741-7015-8-30"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s10096-015-2329-6","article-title":"Quality of life and changes in symptom relief in patients with acute uncomplicated cystitis treated with antibiotics: A prospective, open-label, multicenter, observational study","volume":"34","author":"Choi","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eclinm.2019.06.009","article-title":"Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial","volume":"12","author":"Hertz","year":"2019","journal-title":"EClinicalMedicine"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/3\/314\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:27:53Z","timestamp":1760135273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/3\/314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["antibiotics11030314"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11030314","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202202.0114.v1","asserted-by":"object"}]},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]}}}